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Severe sepsis and septic shock are still deadly conditions urging to develop novel therapies. A better understanding of the complex
modiﬁcationsofthe immunesystem ofseptic patients is needed forthe developmentofinnovative immunointerventions.Natural
killer (NK) cells are characterized as CD3−NKp46+CD56+ cells that can be cytotoxic and/or produce high amounts of cytokines
such as IFN-γ. NK cells are also engaged in crosstalks with other immune cells, such as dendritic cells, macrophages, and
neutrophils. During the early stage of septic shock, NK cells may play a key role in the promotion of the systemic inﬂammation,
as suggested in mice models. Alternatively, at a later stage, NK cells-acquired dysfunction could favor nosocomial infections and
mortality. Standardized biological tools deﬁning patients’ NK cell status during the diﬀerent stages of sepsis are mandatory to
guide potential immuno-interventions. Herein, we review the potential role of NK cells during severe sepsis and septic shock.
1.Introduction
Sepsisistheclinicalpresentationofa“systemicinﬂammatory
response syndrome” (SIRS) to a severe infection. Most clini-
cal and basic-science research on the immune consequences
ofseveresepsisconductedduringthelastdecadeshasfocused
on the roles of macrophages, neutrophilsand conventionalT
lymphocytes[1].Duringrecentyears,however,ithasbecome
increasingly clear that subsets of innate immune cells, such
as natural killer (NK) cells, are involved in both protective
immunity and immunopathology.
Herein, we review the potential role of NK cells during
the diﬀerent stages of severe sepsis and septic shock.
2.SevereSepsis: UrgentNeedsfor
“Immunological” Solutions
The most threatening infections are referred to as severe
sepsis and septic shock [1]. These severe forms of infec-
tion, mainly of bacterial origin, represent a major health-
care problem, accounting for thousands of deaths every
year worldwide, with more than 200,000 deaths per year
just in the United States [2]. Sepsis, severe sepsis, and
septic shock are viewed as a continuum that results in
increasing mortality (cf. Figure 1) and shares consensual
clinical criteria [3]. Mortality is up to 50% in septic
shock, and the incidence of sepsis is projected to increase2 Journal of Biomedicine and Biotechnology
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Figure 1: Continuum from infection to septic shock: the initial
response to pathogen is a systemic response, with release of in-
ﬂammatory mediators and activation of the coagulation cascade,
resulting in imbalance between oxygen delivery and oxygen con-
sumption. Ultimately, tissue hypoxia develops and may lead to
multiple organ dysfunction and irreversible shock.
signiﬁcantly during next years with higher rates of mortality
due to more advanced age and/or associated comorbidities
(cancer, diabetes, etc.). During the last decades, physicians
have made signiﬁcant progress in the early implementation
of symptomatic care through adequate ﬂuid resuscitation,
antibiotherapy, and speciﬁc organ-support techniques, such
as mechanical ventilation and renal-replacement therapy.
Unfortunately, these therapeutic strategies have failed to
suﬃciently reduce mortality in severely septic patients [4,
5]. Moreover, physicians are increasingly concerned about
increasing microbial resistance to antibiotics and the slow
development of new antimicrobial agents [6]. Thus, there is
an urgent need to develop eﬃcacious therapies to treat this
deadly disease.
Future therapies may emerge from a better understand-
ing of the physiopathology of sepsis [7]. Sepsis, also referred
to as SIRS of septic origin, was originally viewed as an
exacerbated inﬂammatory response and a “cytokine storm.”
However,mosttrialsthatusedinhibitorsofproinﬂammatory
cytokines or inhibitors of proinﬂammatory mediators failed
to improve patients’ outcomes, providing the best proof of
the incomplete understanding of its pathogenesis [8, 9]. One
of the reasons for the lack of eﬃcacy of anti-inﬂammatory
strategies in patients with sepsis may be because the syn-
drome changes over time [10].
In its early stages, sepsis is characterized by an increase
in inﬂammatory mediators, but as sepsis persists, there is
a shift towards an anti-inﬂammatory immunosuppressive
state. Indeed, a common feature of these patients is the
alteration of their immune status, referred to as “com-
pensatory anti-inﬂammatory response syndrome” (CARS),
which is thought to render patients more susceptible to
nosocomial infections. It seems that immune dysfunctions
that are supposed to play a role in mortality vary between
patients who succumb within the ﬁrst hour after sepsis and
those who survive the ﬁrst critical hours (>80%) but then
die laterfrom sepsis-induced multiorgan dysfunction and/or
secondary nosocomial infections. It has only been recently
that eﬀorts to understand the eﬀect of the inﬂammatory
process on the immune status during septic shock have fully
integrated the considerable derangements of both the innate
and adaptive immune systems and have better identiﬁed the
contribution of multiple cellular actors [1, 7].
3.NK Cells:EarlySoldierswith
MultipleFunctions
NK cells are lymphocytes that are classically referred to as
part of the innate immunity. NK cells were ﬁrst described for
their ability to kill leukemic cells without prior speciﬁc sen-
sitization [11]. They represent a small proportion (4–15%)
of blood lymphocytes and do not express a speciﬁc receptor
forantigensdependentuponRAG-mediatedrearrangements
[12]. NK cell function is regulated by a multiplicity of acti-
vating and inhibitory receptors. Their natural cytotoxicity is
largely under the control of natural cytotoxicity receptors,
and their antibody-dependent cytotoxicity is linked to the
engagement of CD16/FCγ RIIIa [13]. Human NK cells are
characterized as CD3− NKp46+CD56+ cells [14].Inhumans,
blood NK cells can be divided into two major subtypes:
CD56bright and CD56dim, corresponding to sequential steps
of diﬀerentiation [15]. The former subtype represents
about 10% of circulating NK cells. These cells express
low levels of CD16 and perforin, produce high amounts
of cytokines (e.g., interferon gamma or IFN-γ,T N F - α,
and granulocyte-macrophage colony-stimulating factor) in
response to cytokines such as interleukin (IL)-12 and IL-18,
and represent the major fraction of NK cells in lymph nodes.
CD56dim NK cells express high levels of CD16, perforin,
and killer Ig-like receptors (KIRs). KIRs include inhibitory
receptors that recognize MHC class I molecules and dampen
NKcellactivation. CD56dim NKcellsare cytotoxicbygranule
polarization and exocytosis of various proteins including
perforin and granzymes, which mediate target-cell killing
and are also cytokine producers.
Several lines of evidence suggest that NK cells might
be involved in key functions during sepsis. NK cells have a
major role in defense against viral infections, in particular
herpesvirus [16], inﬂuenza viruses [17], or hantavirus [18],
by direct cytotoxicity against virus-infected cells and by
the early production of cytokines that can control viral
replication, such as IFN-γ. NK cells also participate in
responses to other types of infections, including those
caused by intracellular bacteria, pyogenic bacteria, fungi,
and protozoa [19, 20]. As the early and main producers
of IFN-γ during sepsis, these cells are equipped with many
innate sensors for damage-associated molecular-pattern
molecules (DAMPS) and pathogen-associated molecular-
pattern molecules (PAMPS) [21]. In addition, if NK cells
are found within the blood stream, they are also abundant
in some tissues, such as the lungs [22, 23], an organ par-
ticularly prone to dysfunction in Intensive Care Unit (ICU)
patients. NK cells are also engaged in crosstalks with other
immune cells, such as dendritic cells (DCs) [24], monocytes,Journal of Biomedicine and Biotechnology 3
macrophages [25, 26], and neutrophils [27], which besides
being fundamental for NK cell activation in response to
most pathogens(bydirect contactorcytokinesecretion) also
participate in the development of the subsequent immune
response (Figures 2(A) and 2(B)).
4.NK Cellsand SevereSepsis: Lessonsand
LimitsfromMurineModels
Most of the current knowledge about the role of NK cells
during severe sepsis comes from mouse models. Although
NK cell-deﬁcient mice are not reported to present with
detectable abnormalities at steady state, all data converge
on a detrimental role for NK cells during sepsis. In mice,
a challenge with high doses of lipopolysaccharide (LPS)
results in a syndrome resembling septic shock in humans,
and depletion of NK cells oﬀers protection against LPS-
induced shock [28, 29]. Depletion of NK cells by systemic
administration of polyclonal antiasialo GM1 or monoclonal
anti-NK1.1 antibodies, before the induction of the general-
ized Schwartzman reaction, leads to a dramatic reduction
in mortality and signiﬁcantly lowers cytokine levels (IFN-
γ and TNF-α) following a systemic injection of LPS [28].
T h es a m ep r o t e c t i v ee ﬀect against cytokine-induced shock
(by administrating IL-12 in combination with IL-2 or IL-15)
was observed in mice that underwent depletion of NK cells
with antiasialo GM1 antibodies [30].
In addition, there is now increasing evidence of detri-
mental roles for NK cells in diﬀerent models of bacterial
infections. Depletion of NK cells in SCID mice infected
intranasally with Streptococcuspneumoniaeresultedin signif-
icantlylowerbacteremiaandinﬂammatory cytokineproduc-
tion within the lung airways and lung tissue [31]. Improved
survival was also observed with NK-cell-depleted mice in a
model of septic shock with Streptococcus pneumoniae [32].
In a model of cecal ligation and puncture (CLP), mice
treated with anti-asialo-GM1 were protected against CLP-
induced mortality compared to IgG-treated controls [32].
During CLP-induced shock, NK cells migrated from blood
and spleen to the inﬂamed peritoneal cavity where they
ampliﬁed the proinﬂammatory activities of the myeloid
cell populations [33]. NK cells were also involved in the
high levels of inﬂammatory cytokines, lung pathology, and
mortality that occur during Escherichia coli peritonitis, as all
these parameters were reduced by NK depletion [34].
Altogether, these results suggest that NK cells can pro-
mote the inﬂammatory process occurring during sepsis
in vivo, possibly via interactions with macrophages [35,
36], organ inﬁltration and damage, and the secretion of
proinﬂammatory cytokines, providing a rationale basis to
explain how NK-cell depletion increases survival in exper-
imental sepsis. In opposition to this role of ampliﬁcation
of inﬂammation, recent data show that very early during
t h ec o u r s eo fs y s t e m i ci n f e c t i o n si n d u c e db yToxoplasma
gondii, Listeria monocytogenes,a n dYersinia pestis,I L - 1 2
secreted by DC induces NK cells to produce the broadly
immunosuppressive cytokine IL-10, which, in turn, inhibits
IL-12 secretion by DC, unveiling an immunosuppressive
“regulator” function of NK cells [37]. If documented in
humans, NK cells might then contribute to the necessary
transition from SIRS to CARS (cf. Figure 2).
Mice are the most commonly used animal models in
biomedical research, and rodent studies are an important
part of the preclinical studies that determine progression
to clinical studies in humans during drug development.
However, there are numerous concerns about extrapolation
from what is known about mouse to human NK-cell biology
during severe sepsis, thus limiting the clinical relevance of
the mouse models described above. Because there was no
genetic model where NK cells could be selectively deleted, in
vivo NK-cell depletion has so far relied on anti-asialo-GM1-
or anti-NK1.1-depleting antibodies. Although a depletion of
NKcells canbe obtained with both antibodies, the selectivity
of the depletion depends upon the quantities of antibodies,
blurringtheinterpretationoftheresultsobtainedusing these
methods. More recently, transgenic mice that lack NK cells,
but have a normal T/NKT-cell compartment, have been
reported [38], but the cause of selective NK-cell ablation
in these mice is linked to the expression of the ubiquitous
transcription factor, ATF2, which raises the possibility of
other defects in the immune system [39]. Moreover, the
basic leucine-zipper transcription factor E4BP4 (also called
NFIL3) has been proven essential for the generation of
the NK-cell lineage and E4BP4-deﬁcient mice speciﬁcally
lack NK cells [40]. However, E4BP4-deﬁcient mice were
also shown to undergo impaired B-cell intrinsic IgE class
switching [41]. Finally, taking advantage of the identiﬁcation
of a functional NKp46 promoter, a mouse model of condi-
tional NK cell ablation based on the diphtheria toxin (DT)
receptor/DT-based system has been generated [42]. Because
DT injection leadsto a completeand selective ablation ofNK
cells in these mice, this model provides a precious tool to
explore the role of NK cells in many pathological conditions,
including sepsis.
However, even with the availability of selective NK-cell
deﬁcient models [42] or of humanized mouse models [43],
a constant problem with the murine approach to study
sepsis is that rodents are highly resilient to most models
of induced inﬂammation as compared to humans and that
results depend on the strain and models of sepsis used (from
LPS injection to cecal ligation and puncture). Also, because
the supportive care used in humans is not easily transposed
into mice [44], these models of septic challenge are not fully
relevant to address the particular situation of ICU patients
who survive the most severe sepsis and then come to the
“immunosuppressive” CARS stage, which is responsible for
most deaths.
5.A RoleforNK CellsinHuman SIRS?
By analogy with the possible use of the NK cell-deﬁcient
mouse model, we could consider the study of patients with
NK cell-selective deﬁciency to address the role of NK cells
in severe human sepsis. A number of isolated deﬁciencies
of NK cells in humans have been described, but most
are complex immunodeﬁciencies associated with absent4 Journal of Biomedicine and Biotechnology
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Figure 2: (A) NK cells initiate a local inﬂammatory response to pathogens. (B) During SIRS, NK cells amplify the inﬂammatory response
to the spread of the pathogen, which can lead to organ dysfunction. (C) Deﬁcient NK cell cytotoxicity may favor macrophage activation
syndrome. (D) During CARS, NK cell global dysfunction may favor nosocomial infections. Note: SIRS and CARS have been separated in
time to ease understanding of the ﬁgure, but the diﬀerent stages (B–D) can occur simultaneously. Also, most data shown here are from
mouse models and should be further conﬁrmed in septic patients.
or functionally deﬁcient NK cells [45]. Few reports have
describedpatients with isolated NK-cellabnormalities where
the main susceptibilityis to severeinfection with herpesvirus
[46]. The paucity of nonambiguous cases of NK-selective
deﬁciencies in humans has hampered the identiﬁcation of
nonredundant NK-cell function. Also, as some SCID-X1
patients with no NK cell reconstitution after allogenic bone-
marrow transplantation or gene therapy do not experience
severe infections, it has been suggested that NK cells might
have redundant anti-infectious functions in humans [47].
However,NKcellshavebeenreportedtobekeyincontrolling
severe cytomegalovirus (CMV) infection in some patients
[48]. In septic shock, as fatality can precede adaptive
responses, and in the context of massive and sometimes
persistent apoptosis-induced T- and B-cell lymphopenia
[49], NK cells may play a crucial and nonredundant role.
Our knowledge of NK cells in severe human sepsis and
septic shockcouldbe derived from analyses ofNKcellstaken
directly from patients during the diﬀerent clinical stages of
the disease. However, available data from patients in ICU
are scarce and heterogeneous and do not always include
evaluation of cell function. Because of all these limitations,
these results appear as contradictory. Yet, in patients with
severe Gram-negative sepsis, an increased percentage of
blood NK cells has been reported, as an improved survival in
the patients with high NK counts [50]. Of importance, these
patients did not experience septic shock nor were admitted
into the ICU. Unfortunately, NK cell eﬀector functions were
not monitored in this study. A previous report had observed
that NK-cell counts were higher among patients with sepsis
of Gram-positive origin than among patients with Gram-
negative sepsis [51].
In contrast, previous studies on patients with SIRS [52]
and septic shock [53] had reported reduced numbers of
NK cells and impaired NK cell in vitro cytotoxicity against
K562 tumor cells. However, when NK cell cytotoxicity in
patients with severe sepsis or septic shock was assessed in
vivo by measuring circulating granzyme A and B levels [54],
higher cytotoxicity was found in 50% of septic patients,
and these patients had a higher mortality and worse organ
function. Altogether, as suggested by a recent prospective
study conducted in more than 500 patients with early sepsis,Journal of Biomedicine and Biotechnology 5
the discrepancies concerning the number and/or function of
circulating NK cells are probably due to the heterogeneity of
patientsintermsofeitherseverity(severesepsisand/orseptic
shock) or involvement of pathogens (Gram-negative versus-
positive bacteria) [55].
Also, because septic shock is rapidly associated with a
dramatic decrease in circulating lymphocytes, the timing
of NK-cell analysis might be of particular importance. It
is reported that, from their admission into an ICU, the
numbers of all lymphocyte subpopulations (including NK
cells) of 21 septic-shock patients were diminished, and these
alterations remained stable during the ﬁrst 48h [56], while
no data are available after this short time.
Another caveat in these human studies is that NK cell
testinghasbeenobviouslylimitedtoperipheralblood.AsNK
cells can migrate out of the blood into the inﬂamed tissues,
the interpretation of the analysis may be diﬃcult. Indeed,
the status of NK cells within tissues might be quite diﬀerent
[57, 58]. Only one study has addressed NK cells at a tissular
level in human septic shock. In this paper, Hotchkiss et
al. described a profound and progressive, apoptosis-induced
loss of B and CD4+ T cells in the spleen and gut-associated
lymphoid tissue of adults who had died of sepsis [49]. In
contrast, a trend towards an increase of splenic NK cells
was observed in septic patients. This result failed to reach
statistical signiﬁcance, most likely as the consequence of the
small number of patients.
Thus, with cautiousinterpretation, duetothementioned
heterogeneityinstudiedpatientsandthecompleteabsenceof
data concerning NK cell cytokine secretion, human studies
do not exclude a detrimental role for NK cells in the early
stage of septic shock (Figure 1)t h a tw a so b s e r v e di nm o u s e
models [49, 54].
6.ARoleforNK CellsinHumanCARS?
As the vast majority of patients with sepsis survive the initial
insult, we should consider not only the initial excessive sys-
temic inﬂammatory reaction, but also the following sepsis-
induced immunosuppressive period and its consequences.
During severe sepsis, some patients can develop sec-
ondary hemophagocytic lymphohistiocytic (HLH) syn-
drome, also termed macrophage activation syndrome
(MAS). For intensivists, the features of MAS mainly include
nonremitting fever, severe cytopenias, and organ dysfunc-
tions. MAS is characterized by uncontrolled macrophage
and Th1-lymphocyte stimulation, with elevated levels of
circulating INF-γ,T N F - α, IL-6, and IL-18 [59]. Many clues
to the role of NK cells in MAS have been recently discovered.
First, a marked decrease in NK cell numbers, as well as a
severe decrease in both natural cytotoxicity and ADCC, has
been reported in patients with secondary MAS [60]. Instead
of being just a consequence of MAS, this defect of NK cell
number and function could be part of the pathogenesis.
Indeed, the genetic forms of HLH are characterized by an
intrinsic defect of NK cell and T-cell cytotoxicity related
to the perforin/granzyme release pathway [61], and virally
infectedperforinKOmicerepresentarelevantmodelofMAS
[62].InteractionsbetweenhumanNKcellsandmacrophages
are bidirectional and can result in activation of NKcells orin
the regulation of macrophage activity through the killing of
activated macrophages by NK cells [63]. Thus, even if NK
cells are early and massive sources of INF-γ, and contribute
totheinitialexcessiveinﬂammatory responseinseveresepsis,
a concomitant defect of their cytotoxic functions could
predispose a subset of these septic patients to develop MAS
because NK cell dysfunction may contribute to uncontrolled
Th1-lymphocyte and macrophage activation (Figure 2(C)).
Reduced NK cell numbers and functions, if persistent,
may also contribute to impaired host defenses during CARS
(Figure 2(D)). This “compensatory” inhibitory response,
which is primarily seen as a regulation for hyperinﬂamma-
tion, can then become deleterious as many immune func-
tions are compromised. These alterations may be directly
responsible for the worsening outcome, as they may play
a major role in the decreased resistance to nosocomial
infections in patients who have survived an initial resusci-
tation. In humans, this view is actually merely speculative
as up to now only a single study has been reported,
which includes an evaluation of NK cells in ICU patients
with septic shock that was not restricted to the very early
stage of shock [64]. In this study, NK cell cytotoxicity was
evaluated at diﬀerent time points from admission, and it
was suppressed to <10% in nearly all patients during the
complete observation period (up to 14 days). Interestingly,
ICU patients presenting with septic shock seem more prone
thanotherstodevelopreactivationofCMV[65].TheseCMV
reactivations occurmainly at the late stage of sepsis although
the aﬀected patients seem to have suﬃcient CMV-speciﬁc
CD4+ or CD8+ T cells [64, 66]. These data suggest that
there might be a decrease in NK cell function that favors
the progression of the viral infection. Finally, ICU patients
with CMV reactivation (up to 30% of all ICU patients) may
developmorebacterial/fungalnosocomialinfections because
of the immunosuppressive properties of CMV [65], but one
cannot exclude the possibility that NK cells also participate
in protective immunity against nosocomial pathogens [67].
7.NK Cellsand FutureTherapiesfor
SevereHuman Sepsis:Perspectives
Most of the published data on human sepsis do not
examine bothNKcellnumbersandfunctions and,thus,have
incompletely assessed NK cell status. Nowadays, there are
rapid and relatively inexpensive methods to assess NK cell
functions directly at the patient bedside, using multipara-
metric functional ﬂowcytometry [68].Bothquantitativeand
qualitative evaluation of NK status now needs to be broadly
performed among ICU patients.
Inaddition,asingleparameterwilllikelynotbesuﬃcient
to characterize the complexity of septic patients’ immuno-
logical status, which rapidly changes over time. Therefore,
the introduction ofhigh-throughput technologies represents
an emerging solution for the global immunomonitoring
of sepsis. DNA microarrays and RNAseq allow genome-
wide assessment of changes in mRNA abundance. A ﬁrst
transcriptomic approach could be restricted to NK-speciﬁc6 Journal of Biomedicine and Biotechnology
genes. Strikingly, less than a hundred genes might be
suﬃcient to deﬁne the human NK cell-speciﬁc signature
[69]. One should also look for NKcell-speciﬁc combinations
of more broadly expressed genes during the diﬀerent phases
of severe sepsis. This global functional approach has been
recently performed as a modular approach in diﬀerent
human pathological conditions [70, 71].
As for the potential development of any NK-based
immunointervention, new approaches should also allow to
better deﬁne the complex and dynamic actions of NK cells
during the diﬀerent phases of severe sepsis in humans. At
present, targeted NK cell therapies address hematopoietic
malignancies using diﬀerent strategies to enhance NK cell
functions and promote their antitumor action [72]. These
innovative protocols could be used in the “CARS” period
when ICU patients suﬀer from immunosuppression and
nosocomialinfection.NKcellsstimulationcouldbeachieved
by manipulation of NK receptors (i.e., using anti-KIR-
speciﬁc antibodies that block inhibitory receptors) or by the
administration of cytokines as IL-15. The last option has
provedsuccessful inmurine model ofsepsis and pneumonia,
where administration of IL-15 could prevent apoptosis,
increase the percentage of NK cells that produce IFN-γ,
and reverse immune dysfunction [73]. The restoration of
INF-γ secretion by NK cells that might be able to migrate
and deliver cytokine into the infected tissues at the right
time might be more eﬃcient than the direct parenteral
administration of INF-γ [74]. Alternatively, in the very early
phase of severe sepsis, monoclonal antibodies, targeting, for
example, NKp46, could be also designed to downregulate
or deplete NK cells and prevent the consequences of
uncontrolled inﬂammation due to their gamma interferon
secretion. NK cell depletion should be transient to avoid a
supplementary “immunodepression” due to persistent NK
depletion during CARS. Also, it might be diﬃcult to use it
early enough in patients initiating a septic shock out of the
hospital; but instead, inpatients, for example, presenting a
postsurgical sepsis, could be carefully screened and receive
immunointervention at the earliest phase of sepsis or even
at a presymptomatic phase of sepsis, if it can be robustly
diagnosed [75].
Translation to its clinical application must carefully take
into account the timing of administration of immunother-
apeutical agent. Thus, one of the ﬁrst goals should be
ﬁrst to achieve robust and standardized biological tools
that accurately deﬁne the patient’s immune status, so that
physicians can decidewho can beneﬁt,and when, from those
immunointerventions.
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